Premium
Cancer‐testis antigens as biomarkers for Merkel cell carcinoma: Pitfalls and opportunities
Author(s) -
Dasgeb Bahar,
Mehregan Darius,
Ring Christina,
Nartker Nathan,
Brownell Isaac
Publication year - 2019
Publication title -
journal of cutaneous pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 75
eISSN - 1600-0560
pISSN - 0303-6987
DOI - 10.1111/cup.13528
Subject(s) - antigen , merkel cell carcinoma , staining , immunohistochemistry , immunotherapy , pathology , biology , cancer research , immune system , carcinoma , medicine , immunology
Abstract Background The prognosis and treatment options for metastatic Merkel cell carcinoma (MCC) are poor. The immune‐privileged status of cancer‐testis (CT) antigens imparts tumor specificity, making them ideal candidates for targeted immunotherapy. We investigate the usefulness of the CT antigens SPA17 (sperm protein‐17 [SP‐17]), IGF2BP3 (insulin‐like growth factor‐II mRNA‐binding protein 3 [IMP‐3]), and transmembrane protein with epidermal growth factor (EGF)‐like and two follistatin‐like domains 1 (TMEFF1) as potential MCC biomarkers and evaluate their possible utility in immunotherapy and molecularly targeted image‐guided treatment. Methods The CT antigens SP‐17, IMP‐3, and TMEFF1 were selected using transcriptome profiling to identify CT antigens expressed in MCC tumors. Antibodies directed against these CT antigens were stained. Twelve normal skin tissue samples were used as a control. The average percentage of positive cells in each tumor was computed. Results Twelve of 14 (86%) MCC cases showed crisp nuclear staining for SP‐17, with 2.06% of cells staining positive. IMP‐3 showed crisp, perinuclear staining in all 14 MCC cases, with 52.93% MCC cells staining positive. TMEFF1 showed perinuclear staining in all 14 MCC cases, with 96.51% of tumor cells staining positive. Conclusions CT antigens were found to be expressed in both MCC and some control tissues. SP‐17 was the most specific yet the least sensitive. IMP‐3 and TMEFF1 were both sensitive but not specific. CT antigens may represent valuable treatment targets in MCC.